A 51-year-old man with limb-girdle muscular dystrophy died after receiving Sarepta's experimental gene therapy and experiencing acute liver failure.

The firm will combine every 15 shares into one share in order to comply with Nasdaq's minimum bid price requirement.

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

In a final draft guidance, the committee recommended the treatment for HR-positive HER2-negative early breast cancer patients, regardless of lymph node involvement.

The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...

For $1.8 million upfront and additional contingent and milestone payments, I-Mab gains full rights to givastomig's parental antibody.

The company will pause several gene therapy development programs, for which it intends to seek partners and other strategic alternatives.

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...